LAWRENCE KWONG to Animals
This is a "connection" page, showing publications LAWRENCE KWONG has written about Animals.
Connection Strength
0.474
-
Microparticle-Delivered Cxcl9 Prolongs Braf Inhibitor Efficacy in Melanoma. Cancer Immunol Res. 2023 05 03; 11(5):558-569.
Score: 0.040
-
Insights Into the Origin of Intrahepatic Cholangiocarcinoma From Mouse Models. Hepatology. 2020 07; 72(1):305-314.
Score: 0.033
-
Diagnostic and therapeutic applications of miRNA-based strategies to cancer immunotherapy. Cancer Metastasis Rev. 2018 03; 37(1):45-53.
Score: 0.028
-
A Preexisting Rare PIK3CAE545K Subpopulation Confers Clinical Resistance to MEK plus CDK4/6 Inhibition in NRAS Melanoma and Is Dependent on S6K1 Signaling. Cancer Discov. 2018 05; 8(5):556-567.
Score: 0.028
-
The path to metastatic mouse models of colorectal cancer. Oncogene. 2018 05; 37(19):2481-2489.
Score: 0.028
-
miRNAs, Melanoma and Microenvironment: An Intricate Network. Int J Mol Sci. 2017 Nov 07; 18(11).
Score: 0.027
-
Modeling Genomic Instability and Selection Pressure in a Mouse Model of Melanoma. Cell Rep. 2017 05 16; 19(7):1304-1312.
Score: 0.026
-
Co-clinical assessment identifies patterns of BRAF inhibitor resistance in melanoma. J Clin Invest. 2015 Apr; 125(4):1459-70.
Score: 0.022
-
Chromosome 10, frequently lost in human melanoma, encodes multiple tumor-suppressive functions. Cancer Res. 2014 Mar 15; 74(6):1814-21.
Score: 0.021
-
Navigating the therapeutic complexity of PI3K pathway inhibition in melanoma. Clin Cancer Res. 2013 Oct 01; 19(19):5310-9.
Score: 0.020
-
Oncogenic NRAS signaling differentially regulates survival and proliferation in melanoma. Nat Med. 2012 Oct; 18(10):1503-10.
Score: 0.019
-
The brothers RAF. Cell. 2010 Jan 22; 140(2):180-2.
Score: 0.016
-
The metastasis problem gets stickier. Cancer Cell. 2009 Jan 06; 15(1):1-2.
Score: 0.015
-
APC and its modifiers in colon cancer. Adv Exp Med Biol. 2009; 656:85-106.
Score: 0.015
-
Identification of Mom7, a novel modifier of Apc(Min/+) on mouse chromosome 18. Genetics. 2007 Jun; 176(2):1237-44.
Score: 0.013
-
Convergent MAPK pathway alterations mediate acquired?resistance to FGFR inhibitors in FGFR2 fusion-positive cholangiocarcinoma. J Hepatol. 2024 Feb; 80(2):322-334.
Score: 0.010
-
Neural Crest-Like Stem Cell Transcriptome Analysis Identifies LPAR1 in Melanoma Progression and Therapy Resistance. Cancer Res. 2021 10 15; 81(20):5230-5241.
Score: 0.009
-
A Fatty Acid Oxidation-dependent Metabolic Shift Regulates the Adaptation of BRAF-mutated Melanoma to MAPK Inhibitors. Clin Cancer Res. 2019 11 15; 25(22):6852-6867.
Score: 0.008
-
Induction of Telomere Dysfunction Prolongs Disease Control of Therapy-Resistant Melanoma. Clin Cancer Res. 2018 10 01; 24(19):4771-4784.
Score: 0.007
-
In Vivo E2F Reporting Reveals Efficacious Schedules of MEK1/2-CDK4/6 Targeting and mTOR-S6 Resistance Mechanisms. Cancer Discov. 2018 05; 8(5):568-581.
Score: 0.007
-
Accurate quantification of PGE2 in the polyposis in rat colon (Pirc) model by surrogate analyte-based UPLC-MS/MS. J Pharm Biomed Anal. 2018 Jan 30; 148:42-50.
Score: 0.007
-
Oncogenic Kras drives invasion and maintains metastases in colorectal cancer. Genes Dev. 2017 02 15; 31(4):370-382.
Score: 0.006
-
Synthetic vulnerabilities of mesenchymal subpopulations in pancreatic cancer. Nature. 2017 02 16; 542(7641):362-366.
Score: 0.006
-
Loss of the transforming growth factor-? effector ?2-Spectrin promotes genomic instability. Hepatology. 2017 02; 65(2):678-693.
Score: 0.006
-
MAPK Pathway Inhibitors Sensitize BRAF-Mutant Melanoma to an Antibody-Drug Conjugate Targeting GPNMB. Clin Cancer Res. 2016 Dec 15; 22(24):6088-6098.
Score: 0.006
-
Efficacy of the combination of MEK and CDK4/6 inhibitors in vitro and in vivo in KRAS mutant colorectal cancer models. Oncotarget. 2016 Jun 28; 7(26):39595-39608.
Score: 0.006
-
Oncogenic BRAF-Mediated Melanoma Cell Invasion. Cell Rep. 2016 05 31; 15(9):2012-24.
Score: 0.006
-
Loss of PTEN Promotes Resistance to T Cell-Mediated Immunotherapy. Cancer Discov. 2016 Feb; 6(2):202-16.
Score: 0.006
-
Dual Roles of RNF2 in Melanoma Progression. Cancer Discov. 2015 Dec; 5(12):1314-27.
Score: 0.006
-
Systematic identification of signaling pathways with potential to confer anticancer drug resistance. Sci Signal. 2014 12 23; 7(357):ra121.
Score: 0.006
-
Clinical profiling of BCL-2 family members in the setting of BRAF inhibition offers a rationale for targeting de novo resistance using BH3 mimetics. PLoS One. 2014; 9(7):e101286.
Score: 0.005
-
Passenger deletions generate therapeutic vulnerabilities in cancer. Nature. 2012 Aug 16; 488(7411):337-42.
Score: 0.005
-
microRNA regulatory network inference identifies miR-34a as a novel regulator of TGF-? signaling in glioblastoma. Cancer Discov. 2012 Aug; 2(8):736-49.
Score: 0.005
-
Non-germline genetically engineered mouse models for translational cancer research. Nat Rev Cancer. 2010 Jul; 10(7):470-80.
Score: 0.004
-
A target-selected Apc-mutant rat kindred enhances the modeling of familial human colon cancer. Proc Natl Acad Sci U S A. 2007 Mar 06; 104(10):4036-41.
Score: 0.003